Related Experiment Video
Updated: May 29, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Clinical Outcomes and Prognostic Factors in Patients With Pelvic Sarcomas
Masanori Kawano1, Yuta Kubota2, Ichiro Itonaga2
1Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Japan; kawano@oita-u.ac.jp.
Anticancer Research
|May 27, 2026
Summary
This study found that larger pelvic sarcoma tumor size is linked to worse survival, while carbon-ion radiotherapy (CIRT) shows promise for improving outcomes in these rare cancers.
Area of Science:
- Oncology
- Radiotherapy
- Surgical Oncology
Background:
- Pelvic sarcomas are rare, aggressive tumors with poor prognoses.
- Surgical resection is often challenging due to tumor location and size.
- Optimal treatment strategies for pelvic sarcomas require further investigation.
Purpose of the Study:
- To investigate clinical outcomes in patients with pelvic sarcomas.
- To identify prognostic factors influencing survival in pelvic sarcoma patients.
- To evaluate the role of carbon-ion radiotherapy (CIRT) in pelvic sarcoma treatment.
Main Methods:
- Retrospective review of 20 pelvic sarcoma patients (2015-2025).
- Analysis of clinical characteristics, treatment modalities, and survival outcomes.
- Kaplan-Meier survival analysis and univariate associations.
Main Results:
- Median overall survival (OS) was 33 months and progression-free survival (PFS) was 32 months.
- Larger tumor size (≥95 mm) significantly correlated with poorer OS (OR=21.3, p=0.006).
- Carbon-ion radiotherapy (CIRT) was significantly associated with improved OS (OR=0.05, p=0.007).
Conclusions:
- Tumor size and CIRT utilization are key prognostic factors in pelvic sarcomas.
- Large tumor size indicates unfavorable outcomes, while CIRT may improve survival.
- CIRT shows potential as a treatment option for select pelvic sarcoma patients.
